Aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) may present with arthralgia, myalgia, arthritis or stiffness, and it may be the reason for discontinuation of the treatment in approximately 25% of the patients with early breast cancer [14]. This evidence concerns the gene CYP19A1 and breast cancer.